[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"percutaneous-coronary-intervention-pci\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:percutaneous-coronary-intervention-pci":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,49,78,109,131,163,189,224,258,280,319,342,363,400,426,448,477,506,536,563,583,608],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100627856","efficacy-of-transcutaneous-auricular-vagus-nerve-stimulation-on-alleviating-major-depressive-disorder-in-patients-with-acute-coronary-syndrome-after-percutaneous-coronary-interventiona-prospective-double-blindrandomized-controlled-study-100627856",false,"NCT07454070","Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation on Alleviating Major Depressive Disorder in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention:A Prospective, Double-Blind,Randomized Controlled Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Meeting the diagnostic criteria for ACS\n* 14 days to 12 months after successful PCI, with stable vital signs\n* Meeting the diagnostic criteria for depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V)\n* HAMD-17 score ≥7 and \\\u003C24 (mild-to-moderate depression), with HAMA score \\\u003CHAMD score;\n* Refusal of psychiatric consultation, antidepressant medication, or psychological therapy by the patient or their legal representative after full informed consent\n* Voluntary participation in the study and signing of the informed consent form\n\nExclusion Criteria:\n\n* Severe heart failure (New York Heart Association \\[NYHA\\] class ≥III)\n* Uncontrolled hypertension (systolic blood pressure ≥180 mmHg and diastolic blood pressure ≥110 mmHg)\n* Electrocardiographic abnormalities (first-degree atrioventricular block with PR interval ≥0.20 s, second-degree type II or third-degree atrioventricular block at any time, 24-hour average heart rate ≤50 beats per minute, RR interval ≥3 s) or a history of syncope unrelated to the current ACS\n* Dialysis-dependent patients\n* Previous renal sympathetic denervation or vagal ganglion ablation\n* Expected survival time \\\u003C4 months\n* Pre-PCI diagnosis of severe mental illnesses, including schizophrenia, severe intellectual disability, or substance abuse\n* Current use of antipsychotic medications\n* High suicide risk\n* Pregnant or lactating women\n* Left ear diseases, acute exacerbation of asthma or chronic obstructive pulmonary disease, or other conditions precluding taVNS treatment\n* Implanted cardiac pacemaker, implantable cardioverter-defibrillator (ICD), or other implantable stimulators (e.g., vagus nerve stimulator, deep brain stimulator)","ALL","18 Years",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"NA","This is a randomized, controlled study. ACS follow- up patients aged 18 to 80 years old with hemodynamic stability, who are 14 days to 1 year after PCI, are screened through the HAMD score and the HAMA score. Patients with a HAMD score greater than 7 points and a HAMD score higher than that of the HAMA, are included in this study.\n\nPatients were allocated to the active taVNS group or sham taVNS group with a 1:1 ratio. Both groups received the stimulation for 20 minutes each time, twice a day with an 8-week treatment and a 8-week follow-up.\n\nAll treatments were self-administered by the patients at home after they received training from the hospitals.\n\nThe primary observation endpoints include the depression scores of the HAMD. The secondary observation endpoints include the HAMA 、GAD、 response and remission rates of HAMD ，as well as the PCL-C for post-traumatic stress disorder. We also observed the cardiac function indexes measured by echocardiography and the B-type natriuretic peptide .",[25,26,27,28,29,30,31,32],"Depressive Disorder (Per DSM-V Criteria, Mild-to-moderate)","Acute Coronary Syndrome (ACS)","Percutaneous Coronary Intervention (PCI)","Depressive Disorder","Postoperative Psychological Distress","Heart Rate Variability (HRV)","Inflammatory Factors","Randomized Controlled Trial (RCT)",[34,26,35],"Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)","Post-Percutaneous Coronary Intervention (PCI) Psychological Distress","RECRUITING","2026-06-14",{"date":39,"type":40},"2026-06-16","ACTUAL",{"date":42,"type":40},"2026-01-06",{"date":44,"type":19},"2026-08-10",{"name":46,"class":47},"Jing Han","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100643138","advanced-invasive-diagnosis-strategy-for-post-pci-patients-with-stable-coronary-syndromes-undergoing-coronary-angiography-100643138","NCT07638137","Advanced Invasive Diagnosis Strategy for Post-PCI Patients With Stable Coronary Syndromes Undergoing Coronary Angiography","Advanced Invasive Diagnosis Strategy for Post-PCI Patients With Stable Coronary Syndromes Undergoing Coronary Angiography: the AID Post-PCI Angina Study","Inclusion Criteria:\n\n* Patients with a history of previous percutaneous coronary intervention (PCI) with drug eluting stent (DES), bare metallic stent (BMS), or drug coated balloon (DCB) due to acute coronary syndrome or chronic coronary syndrome, who presented with angina or documented myocardial ischemia by non-invasive testing and are referred for invasive coronary angiography.\n\nExclusion Criteria:\n\n* Acute myocardial infarction (ST-segment elevation myocardial infarction \\[STEMI\\] and non-ST-segment elevation myocardial infarction \\[NSTEMI\\]).\n* Age \\\u003C 18 years old.\n* Pregnancy.\n* Severe left ventricle systolic dysfunction (left ventricular ejection fraction ≤30 %).\n* Congestive heart failure with reduced ejection fraction.\n* Concomitant severe valvular heart disease.\n* Severely decreased renal function (glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2).\n* Significant epicardial coronary artery disease unable to be treated by PCI.\n* Previous coronary artery bypass grafting (CABG).\n* Presence of any anatomic features precluding intracoronary instrumentation with pressure guidewires.\n* Contraindications to the administration of adenosine or acetylcholine.",{"count":57,"type":19},246,"12 Months","OBSERVATIONAL","AID Post-PCI Angina is as an observational, prospective, single-cohort, multicenter study designed to investigate the causes and origins of post-PCI angina by using the advance invasive diagnosis (AID) strategy combining with angiography derived physiology (ADP) in an all-comers population of patients with post-PCI angina referred for invasive coronary angiography. An all-comers population of patients with a history of previous percutaneous coronary intervention (PCI), who presented with angina or documented myocardial ischemia by non-invasive testing and are referred for invasive coronary angiography (ICA) will be enrolled. ICA will be performed with the application of the structure AID strategy to evaluate both obstructive and non-obstructive cause of myocardial ischemia. Then, angiography derived physiological assessment of epicardial coronary artery using functional coronary angiography in each vessel will be performed in both index procedure and the previous procedure in all patients. By combining information obtained from both procedures, the causes and origins of post-PCI angina will be made. Treatment will be decided by the operators according to the result. Patients will complete the Seattle Angina Questionnaire (SAQ) at baseline and at 1, 6, and 12 months after the procedure. The main hypothesis of this study states that, in patients with post-PCI angina referred to ICA, the application of the structured AID strategy combining with angiography derived physiology (ADP) will lead to a high diagnostic yield in identifying the origins of obstructive disease and causes of post-PCI angina.",[62,27,63,64],"Angina (Stable)","INOCA (Ischemia With Non Obstructive Coronary Artery Disease)","Chronic Coronary Syndrome",[66,67,64],"Angina","Percutaneous Coronary Intervention","2026-06-04",{"date":70,"type":40},"2026-06-10",{"date":72,"type":40},"2025-03-12",{"date":74,"type":19},"2028-03-30",{"name":76,"class":47},"Fundacion Investigacion Interhospitalaria Cardiovascular",5,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":20,"phases":88,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100570666","hybrid-percutaneous-coronary-intervention-combining-a-bioresorbable-scaffold-with-drug-coated-balloons-versus-a-conventional-drug-eluting-stent-based-strategy-in-patients-with-long-and-diffuse-coronary-artery-disease-100570666","NCT06710210","Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease","Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease: the BIOHYBRID Randomized Pilot Trial","BIOHYBRID","Inclusion criteria:\n\n* Clinical inclusion criteria\n\n  1. Participant is ≥18 years.\n  2. Participant has provided written informed consent as approved by the independent Ethical Committee (EC) or Institutional Review Board (IRB) of the respective participating centre prior to any study-related procedure.\n  3. Participant is eligible for PCI according to the ESC guidelines (4, 5) .\n  4. Participant is hemodynamically stable.\n  5. Participant with chronic coronary syndrome (CCS) or acute coronary syndrome (ACS): unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), or stabilized ST-segment elevation myocardial infarction (STEMI).\n\n  5a. Participants with STEMI are eligible for the treatment of non-culprit coronary lesions, if participant consent occurs ≥72 hours after successful primary PCI of the culprit STEMI lesion.\n\n  5b. Target lesion(s) to be treated are not located in the STEMI culprit vessel(s) and are not STEMI culprit lesion(s).\n\n  6\\. Participant is eligible for dual antiplatelet therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, or ticagrelor for ≥6 months.\n\n  7\\. Participant is willing to participate and able to comply with the protocol requirements for the duration of the study, including completion of study visits and control coronary angiogram at 12 months.\n\nAngiographic inclusion criteria 8. Target lesion length is \\>40 mm according to operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA), Intravascular Ultrasound (IVUS), or Optical Coherence Tomography (OCT).\n\n9\\. Target vessel has a maximum reference diameter between 3.0-4.6 mm according to operator visual estimation, which may be assisted by QCA, IVUS, or OCT.\n\nNotes: The proximal segment, which has a larger vessel diameter, will be treated with one Freesolve scaffold, in accordance with the vessel diameter range specified in the IFU. The distal segment, which naturally tapers to a smaller diameter, can be treated with one or more Pantera Lux DCB, in accordance with the vessel diameter range specified in the IFU.\n\n10\\. Target lesion with a baseline (pre-PCI) Thrombolysis In Myocardial Infarction (TIMI) flow ≥1.\n\nExclusion criteria:\n\nClinical exclusion criteria\n\n1. Participant has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy or intolerance to aspirin, P2Y12 receptor inhibitors (clopidogrel, ticagrelor, or prasugrel), both heparin and bivalirudin, any of the following DES or bioresorbable scaffold component (magnesium, aluminium, tantalum, poly-L-lactide, or sirolimus), or drug-coated balloon component (paclitaxel).\n2. Participant with STEMI \\\u003C72 hours prior to study index procedure. 12a: Participants with hemodynamically stable NSTEMI are eligible for study enrolment.\n3. Participant with prior PCI within the target vessel during the last 12 months prior to the study index procedure.\n4. Participant is on dialysis or has chronically impaired renal function defined as serum creatinine \\>2.5 mg\u002FdL or 221 μmol\u002FL.\n5. Participant is unable to adhere to DAPT for at least 6 months (e.g. planned surgery, dental surgical procedure, active bleeding disorders, active coagulopathy).\n6. Participant is on oral anticoagulation therapy (OAC) prior to index procedure unless DAPT plus OAC (i.e. triple therapy) can be maintained for a minimum of 1 month.\n7. Participant with life expectancy \\\u003C1 year.\n8. Participant is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study.\n9. Participant is currently participating or planning to participate in another interventional clinical trial, except for observational registries or previous enrolment into the current investigation.\n10. Participant unwilling or unable (e.g. physical or cognitive) to comply with study procedures, medication adherence and schedule.\n11. Contraindications and limitations of the medical devices as described in the instructions for use.\n12. Known or suspected non-compliance, drug or alcohol abuse.\n13. Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.\n14. Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation.\n\n    Angiographic exclusion criteria\n15. Target vessel previously treated with a bare-metal stent or a drug-eluting stent and the target lesion is within 5 mm proximal or distal to the previously treated lesion.\n16. Target lesion is a chronic total occlusion.\n17. Target lesion is located in left main coronary artery, ostial left anterior descending artery, ostial left circumflex artery, or ostial right coronary artery (within 5.0 mm of the vessel origin).\n18. Target lesion is located in, or supplied by, an arterial or venous bypass graft.\n19. Target lesion with excessive tortuosity proximal to or within the lesion based on operator visual estimation, or heavily calcified target lesion which may be adequately prepared using a non-compliant and\u002For cutting\u002Fscoring balloon.\n20. Target lesion requires treatment with a device other than a non-compliant balloon and\u002For a modified (cutting\u002Fscoring) balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy).\n21. Target lesion involves a coronary bifurcation with a side branch with reference vessel diameter ≥2.0 mm that requires a two-device strategy after pre-dilatation.\n22. Presence of thrombus in the target vessel.\n23. Future planned staged PCI or coronary artery bypass graft surgery after the study PCI procedure.\n24. Target with unsuccessful lesion preparation, defined as the absence of residual stenosis ≥30%, TIMI flow grade \\\u003C3 following complete lesion preparation (6), type C to F coronary artery dissection according to the National Heart, Lung and Blood Institute (NHLBI) classification (7) (Appendix 2) and angiographic complications (e.g. distal embolization, or side branch closure).",{"count":87,"type":19},150,[22],"The primary objective of the study is to assess the safety and the efficacy of a hybrid percutaneous coronary intervention (PCI) strategy combining a magnesium-based sirolimus-eluting bioresorbable scaffold (Freesolve, Biotronik AG, Switzerland) and ≥1 paclitaxel-eluting drug-coated balloon(s) (Pantera Lux, Biotronik AG, Switzerland) compared to a conventional DES-based PCI approach using \\>1 newer-generation drug-eluting stents (Orsiro Mission, Biotronik AG, Switzerland) for the treatment of patients with long and\u002For diffuse coronary artery lesions suitable for PCI with respect to vessel-level absolute change in non-invasive angiography-derived fractional flow reserve (FFRangio, CathWorks, Newport Beach, USA) between post-index PCI and 12-month follow-up.\n\nBIOHYBRID is a coronary revascularization strategy study comparing two contemporary treatment approaches for patients with long and\u002For diffuse coronary artery lesions undergoing PCI.\n\nThe primary hypothesis of the study is that a hybrid PCI strategy using a 'leave nothing behind' or 'metal-free' approach that combines a bioresorbable magnesium scaffold and drug-coated balloons for the treatment of patients with long and\u002For diffuse coronary artery lesions suitable for PCI is feasible.\n\nThe secondary hypothesis is that a hybrid PCI strategy combining a bioresorbable magnesium scaffold and drug-coated balloons is non-inferior to a conventional DES-based PCI approach using one or several DES for the treatment of patients with long and\u002For diffuse coronary artery lesions suitable for PCI with respect to vessel-level absolute change in FFRangio (CathWorks, Newport Beach, USA) between post-index PCI and at 12 months of follow-up.",[91,92,27],"Coronary Artery Disease","Diffuse Coronary Artery Disease",[94,95,96,97,98],"Diffuse\u002Flong coronary artery disease","Percutaneous coronary intervention","Drug-eluting stents","Drug-coated balloons","Bioresorbable scaffold","2026-06-01",{"date":101,"type":40},"2026-06-02",{"date":103,"type":40},"2026-04-01",{"date":105,"type":19},"2028-04-01",{"name":107,"class":47},"University Hospital, Geneva",3,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":116,"targetDuration":118,"studyType":59,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":48},"100586760","optimal-stent-deployment-strategy-of-contemporary-stents---registry-to-evaluate-percutaneous-coronary-intervention-using-bioresorbable-scaffolds-with-thinner-strut-construction-and-guidance-by-intracoronary-imaging-to-reduce-scaffold-failure-100586760","NCT06919562","OPtimal stEnt Deployment stRategy oF Contemporary sTents - Registry to Evaluate Percutaneous Coronary Intervention Using Bioresorbable Scaffolds With Thinner-strut Construction and Guidance by intracOronary Imaging to REduce Scaffold Failure","PERFECTRESTORE","Inclusion Criteria:\n\n1. Stable coronary artery disease with one or more significant epicardial stenosis in native coronary arteries suitable for OCT or IVUS-guided PCI with BRS implantation.\n2. Subject must be at least 18 years of age\n3. Written consent to participate in the study\n\nExclusion Criteria:\n\n1. Culprit lesions in the setting of acute coronary syndrome.\n2. Lesions with severe calcification.\n3. Lesions in a coronary artery with severe tortuosity.\n4. Left main coronary artery lesions.\n5. Bifurcation lesions.\n6. Ostial lesions.\n7. Lesions with a difference in proximal and distal reference diameter of \\>0.5 mm by visual judgement of the coronary angiogram by the treating operator.\n8. Treatment of in-stent restenosis or stent thrombosis.\n9. History of definite stent thrombosis.\n10. Lesions in coronary artery bypass grafts.\n11. Lesions not suitable for OCT or IVUS catheter delivery and imaging, e.g. due to tortuosity or distal localisation.\n12. Creatinine Clearance ≤ 30 ml\u002Fmin\u002F1.73 m2 as calculated by MDRD formula for estimated GFR.\n13. Contraindication to dual antiplatelet therapy with aspirin and a P2Y12 inhibitor or (if indicated) NOAC and P2Y12 inhibitor.\n14. Planned non-deferrable major surgery after PCI.\n15. Known comorbidity associated with a life expectancy \\\u003C1 year.\n16. Unable to understand and follow study-related instructions or unable to comply with study protocol.",{"count":117,"type":19},117,"3 Years","Implantation of a metallic drug-eluting stent (DES) is currently the gold standard in percutaneous coronary intervention (PCI). However, a DES has several limitations on the long-term, such as chronic local inflammation which may lead to in-stent restenosis, absence of physiological coronary vasomotion and vessel caging which makes future coronary artery bypass grafting (CABG) impossible. A bioresorbable scaffold (BRS) is designed to overcome these limitations. The first generation BRS was shown to be clinically inferior to DES due to a slightly higher rate of stent thrombosis. To overcome this problem, several scientific developments have been achieved in the past few years, such as thinner BRS strut construction and improved implantation technique by using PSP (predilatation, sizing, postdilatation) method and intracoronary imaging guidance with optical coherence tomography (OCT) or intravasculair ultrasound (IVUS). A PCI protocol that combines implantation of a second generation thin-strut BRS, mandatory PSP implantation method and mandatory intracoronary imaging-guidance has not yet been investigated. The aim of this study is to investigate feasibility of a new PCI protocol with implantation of the second generation Meres100 thin-strut BRS combined with a protocolized PSP implantation technique guided by intracoronary imaging.",[121,27],"Coronary Arterial Disease (CAD)","2026-05-15",{"date":124,"type":40},"2026-05-18",{"date":126,"type":40},"2025-11-04",{"date":128,"type":19},"2030-08",{"name":130,"class":47},"Albert Schweitzer Ziekenhuis, Netherlands",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":139,"enrollmentInfo":140,"targetDuration":142,"studyType":59,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":158,"leadSponsor":160,"locationsCount":48},"100635788","chip-cc-registry-a-prospective-multicenter-registry-of-complex-high-risk-pci-in-china-100635788","NCT07557238","CHIP-CC Registry: A Prospective Multicenter Registry of Complex High-Risk PCI in China","A Prospective, Multicenter, Observational Registry to Evaluate Clinical Outcomes and Prognostic Factors in Patients Undergoing Complex High-Risk Indicated Percutaneous Coronary Intervention in China","CHIP-CC","Inclusion Criteria:\n\nParticipants must meet all of the following criteria:\n\n1. Age 18 to 90 years.\n2. Willing and able to comply with the study protocol and data collection procedures, able to understand the purpose of the study, and willing to provide written informed consent.\n3. Considered by the heart team to have an indication for coronary revascularization but to be at high risk for coronary artery bypass grafting, or the patient declines coronary artery bypass grafting, and PCI is considered potentially beneficial after heart team evaluation.\n4. Left ventricular ejection fraction ≤35%, or left ventricular ejection fraction ≤40% with severe mitral regurgitation.\n5. Undergoing complex PCI with at least one of the following features:\n\n   * Unprotected left main coronary artery disease;\n   * PCI of the last remaining patent coronary artery;\n   * Three-vessel coronary artery disease;\n   * Calcified coronary lesion requiring rotational atherectomy;\n   * Chronic total occlusion requiring bilateral angiography or retrograde techniques.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria will be excluded:\n\n1. Acute ST-segment elevation myocardial infarction within 1 week before enrollment.\n2. Cardiogenic shock, defined by all of the following:\n\n   * Systolic arterial blood pressure \\\u003C90 mmHg for ≥30 minutes, or need for vasopressors, inotropes, or mechanical circulatory support to maintain systolic arterial blood pressure ≥90 mmHg;\n   * Evidence of reduced cardiac output, such as cardiac index \\\u003C2.2 L\u002Fmin\u002Fm²;\n   * Evidence of end-organ hypoperfusion, including cold extremities, urine output \\\u003C30 mL\u002Fhour, altered mental status, or lactate \\>2 mmol\u002FL.\n3. Unable to complete the planned follow-up.\n4. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the registry.","90 Years",{"count":141,"type":19},1000,"2 Years","This is a prospective, multicenter, observational registry designed to evaluate clinical outcomes in patients undergoing complex high-risk indicated percutaneous coronary intervention (CHIP-PCI) in China. Eligible patients will be adults with complex coronary artery disease and severely reduced left ventricular function, or reduced left ventricular function with severe mitral regurgitation, who are considered by the heart team to have an indication for coronary revascularization but are at high risk for coronary artery bypass grafting or decline surgical revascularization.\n\nThe registry will collect baseline clinical characteristics, coronary angiographic and procedural data, use of intravascular imaging or physiological assessment, revascularization strategy, mechanical circulatory support, peri-procedural complications, laboratory and echocardiographic data, and follow-up outcomes. The primary endpoint is all-cause mortality at 1 year after PCI. Secondary endpoints include major adverse cardiovascular events, cardiac death, myocardial infarction, target vessel revascularization, heart failure hospitalization, major bleeding, and quality-of-life measures. The study also aims to identify prognostic factors and develop a risk prediction model for patients undergoing CHIP-PCI.",[91,145,27],"High Risk PCI",[147,148,67,91,149,150,151,152],"CHIP","complex high-risk PCI","left ventricular dysfunction","mechanical circulatory support","clinical outcomes","real-world registry","NOT_YET_RECRUITING","2026-05-07",{"date":156,"type":40},"2026-05-12",{"date":99,"type":19},{"date":159,"type":19},"2029-12-31",{"name":161,"class":162},"Guofeng Gao","OTHER_GOV",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":20,"phases":173,"briefSummary":175,"conditions":176,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100512662","phase-4-monotherapy-with-p2y12-inhibitors-in-patients-with-atrial-fibrillation-undergoing-supraflex-stent-implantation-100512662","NCT05955365","Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation","Monotherapy With a P2Y12 Inhibitor Followed by a Direct-acting Oral Anticoagulant in Patients With ATRial fIbrillation Undergoing suprafleX Cruz Coronary Stent Implantation","MATRIX-2","Inclusion Criteria:\n\n* Age ≥18 years\n* Atrial fibrillation or flutter with an indication for oral anticoagulation using direct-acting oral anticoagulants (DOACs) for ≥12 months\n* Successful percutaneous coronary intervention in at least 1 lesion within the previous 7 days with no remaining lesions intended for treatment.\n* Free from major adverse events post qualifying PCI, including new onset chest pain suspected to be of ischemic origin, acute or subacute stent thrombosis, new-onset neurological signs or symptoms.\n* Written informed consent\n\nExclusion Criteria:\n\n* Planned staged percutaneous intervention procedure (Patients can be enrolled after complete coronary revascularization with no remaining lesions intended for treatment. Patients who have or develop indication to percutaneous valve intervention can undergo treatment more than 30 days after qualifying PCI.)\n* Cardioversion for treatment of atrial fibrillation within 1 month prior to inclusion or planned cardioversion\n* AF ablation procedure within 2 months prior to inclusion or planned AF ablation procedure\n* Prior mechanical valvular prosthesis implantation\n* Deep vein thrombosis\u002Fpulmonary embolism, at least moderately severe mitral stenosis or other clinical conditions than atrial fibrillation requiring long-term oral anticoagulation\n* Stroke within 1 month prior to randomization\n* Hemodynamic instability (persistent systolic blood pressure below 90 mmHg, continuous infusions of catecholamines, clinical signs of hypoperfusion and\u002For use of percutaneous left ventricular assist devices)\n* Uncontrolled severe hypertension with a systolic blood pressure (BP) ≥180 mmHg and\u002For diastolic BP ≥120 mmHg\n* Severe renal impairment with estimated creatinine clearance (CrCL) \\\u003C15 mL\u002Fmin or on dialysis\n* Moderate or severe hepatic impairment (Child-Pugh Class B or C) or any hepatic disease associated with coagulopathy\n* Any hypersensitivity or contraindications for direct oral anticoagulation or dual antiplatelet therapy with aspirin and a P2Y12 inhibitor\n* Any of the following abnormal local laboratory results prior to randomization: platelet count \\\u003C50 x109\u002FL or hemoglobin \\\u003C8 g\u002FdL\n* Known pregnancy or breast-feeding patients\n* Life expectancy \\\u003C1 year due to other severe non-cardiac disease\n* Planned surgery including coronary artery bypass grafting within the next 6 months",{"count":172,"type":19},3010,[174],"PHASE4","Patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation require treatment with different antithrombotic drugs. Oral anticoagulants are prescribed to reduce the risk of stroke associated with atrial fibrillation. Antiplatelet substances are prescribed after stent implantation to reduce the risk of adverse cardiac events such as myocardial infarction or stent thrombosis. Treatment with antithrombotic medications can cause bleeding complications, particularly when these substances are combined.\n\nThe currently recommended standard strategy consists of treatment with 3 antithrombotic medications for at least 1 week up to one month, followed by treatment with two of these medications for up to 6-12 months after stent implantation. Thereafter, patients usually receive long-term treatment with only one drug, an anticoagulant.\n\nIn the monotherapy group of this study, the investigators will investigate a strategy where only one antithrombotic drug will be used at a time. During the first month after stent implantation, the investigators will prescribe an antiplatelet medication, followed by an oral anticoagulant as monotherapy. This strategy might be associated with fewer bleeding complications, while protecting adequately against thrombotic events.\n\nIn this study the investigators would like to investigate whether treatment with a single antithrombotic drug (\"monotherapy strategy\") is associated with benefits compared to the currently recommended combination therapy of antithrombotic medications (\"standard-of-care strategy\").",[27,177,178,179],"Atrial Fibrillation (AF)","Oral Anticoagulation","P2Y12 Inhibitor",{"date":181,"type":40},"2026-05-08",{"date":183,"type":40},"2023-12-18",{"date":185,"type":19},"2028-06-30",{"name":187,"class":47},"Insel Gruppe AG, University Hospital Bern",15,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":20,"phases":200,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":48},"100595896","leave-nothing-behind-study-which-compares-dcb-with-bail-out-brs-versus-brs-strategy-alone-100595896","NCT07038408","Leave Nothing Behind Study Which Compares DCB With Bail Out BRS Versus BRS Strategy Alone","Multi-center, Open-label, Prospective, Randomized Study to Show Long-term Efficacy of DCB Treatment With Bail-out BRS in Comparison to BRS Treatment of De-novo Native Coronary Artery Lesions in a Relatively Young PCI Population.","LNB","Inclusion Criteria:\n\n* Patients aged ≥ 18 years ≤ 68 years\n* Single vessel or multivessel disease with low to moderate complex de-novo native coronary artery lesions up to 30 mm length and reference vessel diameter 2.75-4.0 mm\n* Maximum of 3 target lesions\n* Maximal cumulative lesion length of all treated lesions 80 mm\n* Signed informed consent for participation in the study\n\nExclusion Criteria:\n\n* ST-segment Elevation Myocardial Infarction (STEMI) treatment at index or in the previous 48 hours\n* Severe calcified lesions\n* Bifurcations lesions with planned 2 device strategy\n* Left-Main (LM) disease ≥ 50% diameter stenosis\n* More than 3 target lesions\n* Renal insufficiency with Glomerular Filtration Rate (GFR) \\\u003C 45 ml\u002Fmin\n* Life expectancy less than 1 year\n* Known hypersensitivity or allergy to aspirin or P2Y12 receptor inhibitors\n* Incapable of providing written informed consent\n* Pregnant or breastfeeding women\n* Under judicial protection, tutorship, or curatorship\n* Participation in another trial","68 Years",{"count":199,"type":19},2256,[22],"The goal of this study is to investigate the equivalence in early and long-term efficacy between the two \"Leave nothing behind strategies\" (Drug-Coated Baloon \\[DCB\\] strategy with bail-out BioResorbable Scaffold \\[BRS\\] versus BRS strategy) of de-novo native coronary artery lesions in a relatively young Percutaneous Coronary Intervention (PCI) population, to be more specific, Patients with Chronic Coronary Syndromes (CCS) and Acute Coronary Syndrome (ACS) (Non-ST-segment Elevation Myocardial Infarction \\[NSTEMI\\] and Unstable angina) between 18-68 years of age scheduled for PCI. The main questions aim to answer are:\n\nDCB strategy with bail-out BRS implantation has equivalent clinical outcomes at 12 months compared to BRS strategy? DCB strategy with bail-out BRS implantation has noninferior angiographic in-segment net gain at 13 months compared to BRS strategy? DCB strategy with bail-out BRS implantation has equivalent clinical outcomes at 60 months compared to BRS strategy?\n\nParticipants will be followed at:\n\n1. st FU visit - 1 month (in hospital)\n2. nd FU visit - 6 months (telephone)\n3. rd FU visit - 365 days±15 days (telephone) - 1Y Primary efficacy endpoint\n4. th FU visit - 395 days±15 days (in hospital) co-primary efficacy endpoint for the angiographic substudy\n5. th FU visit - 730 days±30 days (telephone call) - 2Y\n6. th FU visit - 1095 days±30 days (telephone call) - 3Y\n7. th FU visit - 1460 days±30 days (telephone call) - 4Y\n8. th FU visit- 1825 days±30 days (telephone call) - 5Y",[203,204,27,26],"Drug Coated Balloon","Bioresorbable Scaffold",[206,207,208,209,210,211,212,213],"MULTI-CENTER","OPEN-LABEL","PROSPECTIVE","RANDOMIZED STUDY","LONG-TERM EFFICACY OF DCB TREATMENT WITH BAIL-OUT BRS","BRS TREATMENT","DE-NOVO NATIVE CORONARY ARTERY LESIONS","YOUNG PCI POPULATION","2026-04-27",{"date":216,"type":40},"2026-04-30",{"date":218,"type":40},"2026-04-24",{"date":220,"type":19},"2032-03",{"name":222,"class":223},"Ceric Sàrl","INDUSTRY",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":20,"phases":234,"briefSummary":235,"conditions":236,"keywords":242,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":257},"100572699","orbital-atherectomy-vs-intravascular-lithotripsy-for-the-treatment-of-calcified-coronary-nodules-orbit-shock-100572699","NCT06736665","Orbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK).","Comparative Efficacy of Orbital Atherectomy and Intravascular Lithotripsy in the Treatment of Calcified Coronary Nodules. The ORBIT-SHOCK Pilot Study.","ORBIT-SHOCK","Inclusion Criteria:\n\n1. Patients aged ≥ 18 years.\n2. Atherosclerotic coronary artery disease with calcified nodules identified by OCT in a native vessel, eligible for percutaneous coronary revascularization.\n3. Clinical presentation of chronic coronary syndrome or acute coronary syndrome without ST elevation\\*.\n4. Distal vessel reference diameters ≥ 2.5 mm and ≤ 4.0 mm. \\* Non-culprit lesions eligible for revascularization in a staged procedure following a ST-elevation myocardial infarction (STEMI) are considered for inclusion.\n\nExclusion Criteria:\n\n1. Culprit lesions in acute coronary syndrome with ST elevation.\n2. Left main disease.\n3. In-stent restenosis lesions.\n4. Critical stenoses where it is not possible to advance the OCT catheter across the lesion after predilation with a balloon of up to 2 mm in diameter.\n5. Lesion involving a bifurcation with a secondary branch diameter ≥2 mm.\n6. Cardiogenic shock.\n7. Patients requiring cardiac surgery or percutaneous valve intervention within three months before or after angioplasty.\n8. Pregnancy.\n9. Life expectancy of less than one year.\n10. Contraindication for the use of appropriate antiplatelet therapy post-revascularization.\n11. Coronary artery disease with an indication for surgical revascularization.\n12. Advanced chronic kidney disease or anatomical characteristics that contraindicate the use of optical coherence tomography.\n13. Inability to obtain informed consent.\n14. Allergy to eggs or soy, contraindicating the use of OA.",{"count":233,"type":19},50,[22],"The ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting calcified nodules (CN), identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI).\n\nPatients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).\n\nThe ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting calcified nodules (CN), identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI). Patients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).\n\nThe aim of this pilot trial is to compare PCI outcomes and the incidence of adverse events between both techniques.",[121,237,238,239,240,241,27,64,26],"Coronary Calcification","Coronary Calcified Nodules","Orbital Atherectomy","Intravascular Lithotripsy","Optical Coherence Tomography (OCT)",[243,244,245,246,247,241,27,64,26,230,248],"Coronary arterial disease","Coronary calcification","Coronary calcified nodules","Orbital atherectomy","Intravascular lithotripsy","ORBIT SHOCK","2026-04-26",{"date":216,"type":40},{"date":252,"type":40},"2025-06-12",{"date":254,"type":19},"2027-12",{"name":256,"class":47},"Spanish Society of Cardiology",6,{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":20,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":48},"100586526","phase-4-prasugrel-monotherapy-reduced-dose-in-acute-and-chronic-coronary-syndrome-patients-after-percutaneous-coronary-intervention-promote-100586526","NCT06916520","Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)","Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention","PROMOTE","Inclusion Criteria:\n\n* Acute Coronary Syndrome\n* Chronic Coronary Syndrome\n* Successful PCI\n\nExclusion Criteria:\n\n* Known allergy or contraindication for prasugrel, including Active pathological bleeding Severe liver disease (defined as Child Pugh class C)\n* Current indication for oral anticoagulant therapy (OAC)\n* Indication for ongoing DAPT (e.g. PCI ≤ 6 months for CCS or ACS ≤ 12 months)\n* Pregnancy or breast-feeding women\n* Participation in another trial with an investigational drug or device\n* Recent or ongoing use of CYP2B6 substrates with a narrow therapeutic window (e.g. cyclophosphamide, efavirenz)",{"count":267,"type":19},300,[174],"Rationale: Dual antiplatelet therapy, consisting of aspirin and a P2Y12-inhibitor, reduces the risk of stent-related and non-stent-related ischemic events after percutaneous coronary intervention (PCI). However, this therapy is also associated with a higher risk of bleeding. Given the advances in stent technology and pharmacology, it may be possible to treat patients undergoing PCI with low dose prasugrel as single antiplatelet therapy, regardless of medical history, age or body weight.\n\nObjective: Assess the feasibility and safety of a single antiplatelet strategy with a reduced dose of prasugrel 5 mg after PCI in acute and chronic coronary syndrome patients (ACS and CCS).\n\nStudy design: Open-label, single-centre, randomized controlled trial.\n\nStudy population: Patients undergoing successful PCI due to acute or chronic coronary syndrome.\n\nIntervention: A once-daily reduced dose of 5 mg prasugrel for 6 months in CCS patients and for 12 months in ACS patients, preceded by a loading dose of 60 mg prasugrel after PCI, administered without concomitant use of aspirin.\n\nMain study parameters\u002Fendpoints: The primary endpoint is Net Adverse Clinical Events (NACE), a composite of all-cause death, myocardial infarction, definite stent thrombosis, ischemic stroke, clinically relevant non-major bleeding or major bleeding defined as Bleeding Academic Research Consortium type 2, 3 or 5.",[121,27],"2026-03-02",{"date":273,"type":40},"2026-03-04",{"date":275,"type":40},"2025-11-13",{"date":277,"type":19},"2027-04",{"name":279,"class":47},"J.P.S Henriques",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":15,"minAge":288,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":20,"phases":292,"briefSummary":293,"conditions":294,"keywords":299,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":318},"100576667","aerobic-exercise-induced-effect-on-endothelial-function-in-patients-with-ischaemic-heart-disease-100576667","NCT06788275","Aerobic Exercise-induced Effect on Endothelial Function in Patients With Ischaemic Heart Disease","Effect of Different Aerobic Exercise Methods in Cardiac Rehabilitation on Endothelial Function in Patients With Ischaemic Heart Disease and Study of the Associated Physiological Mechanisms (ENDO-R)","ENDO-R","Inclusion Criteria:\n\n* Men and women aged between 45 and 75 years.\n* Diagnosed with acute myocardial infarction, unstable or stable angina.\n* Treated with percutaneous coronary intervention, coronary artery bypass grafting, or conservative treatment.\n* Event or intervention within 3 to 12 months prior to participation in the study.\n* Fluency in speaking and reading Spanish.\n* Residing in Elche or surrounding areas and able to attend evaluations and the exercise programme (not planning to be absent for more than one week during the programme).\n* Functional Class I-II according to the New York Heart Association (NYHA) classification.\n* No physical limitations for exercise.\n* Stable optimal medical treatment.\n* Physically inactive, defined as 1) not meeting the World Health Organization recommendations for both aerobic and strength exercise, and 2) not participating in a structured exercise programme at least 3 days per week for more than 3 months. Both conditions must be met for inclusion. Note: Casual walking is not considered grounds for exclusion.\n\nExclusion Criteria:\n\n* Use of walking assistive devices.\n* Treatment with chemotherapy for any type of cancer in the past 2 years.\n* Hospitalisation in an intensive care unit in the past 6 months for reasons other than the ischaemic event.\n* Acute myocardial infarction group IV Killip-Kimball.\n* Obesity grade III (≥40.0 kg\u002Fm²).\n* Medical contraindication for inclusion in an exercise programme.\n* Diabetes with uncontrolled blood glucose levels.\n* Poorly controlled hypertension: resting blood pressure \\> 180\u002F110 mmHg.\n* Chest pain with exertion or ST-segment changes suggestive of residual ischemia during ergometry. Residual ischemia.\n* Severely reduced functional capacity on initial ergometry (\\<5 metabolic equivalent of task).\n* Left ventricular ejection fraction less than 50%.\n* Severe stenosis of the left main coronary artery (\\>50% significant disease).\n* Severe aortic stenosis, left ventricular outflow tract obstruction (e.g., obstructive hypertrophic cardiomyopathy) or aortic dissection.\n* Severe valvulopathy.\n* Acute pulmonary embolism or deep vein thrombosis.\n* Severe pulmonary hypertension.\n* Acute heart failure.\n* Acute endocarditis, myocarditis, or pericarditis.\n* Acute or chronic renal insufficiency (estimated glomerular filtration rate \\<30 ml\u002Fmin).\n* Pulmonary fibrosis or interstitial disease (severe respiratory insufficiency or confirmed chronic obstructive pulmonary disease).\n* Uncontrolled cardiac arrhythmias\u002Fhemodynamically unstable.\n* Permanent or persistent\u002Fparoxysmal atrial fibrillation with episodes in the past 6 months.\n* High-grade cardiac block.\n* Presence of implantable devices: cardiac resynchronization therapy pacemaker, implantable cardioverter defibrillators, or pacemaker.\n* Presence of ischaemic symptoms during the incremental exercise test performed before the intervention.\n* Severe autonomic or peripheral neuropathy.\n* Use of nitrates in pharmacological treatment.\n* Any planned surgical or medical intervention during the study period.\n* Plans to participate in or current participation in other studies that may interfere with this study.\n* Current pregnancy or intention to become pregnant during the study period.","45 Years","75 Years",{"count":291,"type":19},132,[22],"Endothelial dysfunction is one of the aetiological factors in ischaemic heart disease (IHD). Aerobic exercise is effective in improving endothelial function, as measured by flow-mediated dilation (FMD), in patients with IHD. Within the aerobic exercise methods, there is evidence showing that high-intensity interval training (HIIT) increases FMD to a greater extent than moderate-intensity training (MIT) in these patients. Notably, in a recent review, our research group found that only studies performing long bouts of HIIT (long HIIT: higher than 1 min) found a greater effect on FMD, while no differences were found in those studies using short bouts of HIIT (short HIIT: ≤ 1 min) and MIT. However, no experimental studies comparing the effect of long HIIT, short HIIT, and MIT on endothelial function, as well as other predictors of mortality, such as cardiorespiratory fitness, brain-derived neurotrophic factor (BDNF) levels or parasympathetic branch activity, have been performed. Therefore, the main objective of this project will be to compare the effect of the three aerobic exercise methods on endothelial function, as measured by FMD, in patients with IHD. Complementarily, the effect of aerobic exercise, depending on the exercise method, on different mortality predictors will be compared. For this purpose, a multicentre randomised study will be carried out (2 hospitals in Elche and one in Alicante). Assessors will be blinded to the patients allocation. Participants will be aware about their allocation in the experimental groups due to the nature of the study. A total of 132 men and women with IHD (66 per sex), diagnosed between three and 12 months before the start of the intervention, aged between 45 and 75 years, and without limitations for the practice of exercise training, will be recruited. All patients will train 3 days a week for 12 weeks. Participants will be assessed before the intervention (i.e., pre), at 6 weeks of training (i.e., mid) and after the intervention (i.e., post). Physiological and psychological variables will be registered in the assessment periods. Training intensity will be individually prescribed based on the cardiopulmonary exercise test (CPET). Intensity exercise will be adapted after the first part of the intervention. Analysis of covariance will be used to compare the values of the three groups after the intervention for the continuous variables, including the pre-intervention value as a covariate, while a logistic regression model will be used for the categorical variables.",[27,295,62,296,297,298],"Acute Myocardial Infarction","Unstable Angina Pectoris","Cardiorespiratory Fitness","Ischaemic Heart Diseases",[300,301,302,303,304,305,306,307],"Aerobic exercise","High-intensity interval training","Cardiac rehabilitation","Multicenter study","Coronary artery disease","Flow-mediated dilation","Nitroglycerin-mediated dilation","Mortality predictors","2026-02-25",{"date":310,"type":40},"2026-02-27",{"date":312,"type":40},"2024-11-01",{"date":314,"type":19},"2027-11",{"name":316,"class":317},"Instituto de Investigación Sanitaria y Biomédica de Alicante","NETWORK",2,{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":328,"conditions":329,"keywords":330,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":48},"100626966","drug-coated-balloon-vs-drug-eluting-stent-in-patients-with-coronary-artery-disease-100626966","NCT07442500","Drug Coated Balloon vs. Drug-eluting Stent in Patients With Coronary Artery Disease","DCB_DES","Inclusion Criteria:\n\n* Patients with coronary artery disease undergoing percutaneous coronary intervention\n* Used devices number less than three (relatively simple lesion)\n\nExclusion Criteria:\n\n* Hybrid strategy (DCB and DES use)\n* Failed percutaneous coronary intervention\n* Previous revascularization procedure before index percutaneous coronary intervention",{"count":327,"type":19},470000,"Studies exploring the feasibility of drug-eluting balloon (DCB) in de-novo coronary lesions are limited. There are scarce data comparing DCB with drug-eluting stent (DES) in patients with high bleeding risk (HBR), a situation in which long-term maintenance of dual antiplatelet therapy (DAPT) is a clinical dilemma. This target trial emulation aims to compare clinical outcomes between DCB angioplasty and conventional DES implantation in de-novo coronary lesions in patients with coronary artery disease.",[91,27],[331,332,333],"Drug coated balloon","Drug-eluting stent","High bleeding risk","2026-02-24",{"date":271,"type":40},{"date":337,"type":19},"2026-02-28",{"date":339,"type":19},"2026-12-31",{"name":341,"class":47},"Samsung Medical Center",{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":362},"100585104","the-3d-stent-study-100585104","NCT06898021","The 3D Stent Study","Diagnostic Performance of 3DStent to Assess Stent Expansion","Inclusion Criteria:\n\n* Patient presenting with chronic or acute coronary syndromes (ACS) with a clinical indication for PCI guided by IVUS.\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Coronary lesions requiring total stent length \\> 48 mm.\n3. Body mass index \\>35 kg\u002Fm2\n4. Uncontrolled recurrent ventricular tachycardia\n5. Cardiogenic shock\n6. Unable to provide written informed consent (IC).",{"count":350,"type":19},200,"The goal of this observational study is to assess the diagnostic performance of 3D Stent to detect stent under-expansion in patients undergoing percutaneous coronary intervention.\n\nThe main question it aims to answer is:\n\nThe study hypothesis is that 3DStent technology will offer a comparable assessment of stent expansion compared to intravascular imaging.",[91,27],"2026-01-09",{"date":355,"type":40},"2026-01-12",{"date":357,"type":40},"2025-04-11",{"date":359,"type":19},"2027-12-31",{"name":361,"class":223},"CoreAalst BV",4,{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":368,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":20,"phases":372,"briefSummary":373,"conditions":374,"keywords":384,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":318},"100617275","optimal-strategy-to-correct-stent-underexpansion-in-resistant-lesions-100617275","NCT07316504","Optimal Strategy to Correct Stent underexpAnsion in Resistant Lesions","OSCAR","Inclusion criteria :\n\n* Patient who have undergone coronary angiography with ISR, defined as ≥50% reduction of the diameter of the intrastent lumen occurring ≥ 6 months after stent implantation\n* And with a suspicion of stent under-expansion on angiography, possibly assisted by a stent enhancement technique\n* The reference diameter of the target vessel must be ≥2.5 mm and ≤5.0 mm.\n* Coronary flow must be TIMI 3\n* Ability to cross the lesion with the OCT catheter (possibly after predilatation with a balloon up to 2 mm)\n* Patient affiliated to the French National Health Insurance\n\nExclusion criteria :\n\n* Heart failure with NYHA III or IV (or cardiogenic shock)\n* LVEF \\\u003C20%\n* Chronic renal failure with clearance \\\u003C30mL\u002Fmn according to CKD\n* Pregnant or breast-feeding women\n* Patient with a condition\u002Fcomorbidity that could reduce compliance with the protocol, including pre-specified study follow-up\n* Patient participating in another ongoing medical study evaluating a pharmacological or biological agent or medical device, unless authorized by the concomitant protocol.\n* Patient unable to tolerate double antiaggregation (i.e., aspirin and clopidogrel or prasugrel or ticagrelor) for at least 6 months.\n* Possible or defined thrombus (by angiography or endovascular imaging) in the target vessel.",{"count":371,"type":19},80,[22],"Percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) accounts for 5-10% of PCI. ISR may be linked to mechanical complications mainly under-expansion (UE), neointimal hyperplasia and\u002For neoatherosclerosis. International guidelines recommends non-compliant and very-high-pressure balloons, which lead to sub-optimal angiographic and clinical results. Recently, observational studies have suggested the feasibility and safety of intravascular lithotripsy (IVL) in UE treatment. There are no prospective randomised controlled studies comparing intravascular lithotripsy with balloons in ISR with UE.",[375,376,377,378,379,27,380,241,381,240,91,382,383],"Coronary Angioplasty","Restenosis","Lithotripsy","Restenosis of Coronary Artery Stent","Angioplasty, Transluminal, Percutaneous Coronary","OCT Angiography","Intravascular Lithotripsy; Rotational Atherectomy; OFDI","Coronary Artery Disease (CAD)","Coronary Stent Restenosis",[385,386,387,388,389,390,95],"restenosis","underexpansion","intrastent restenosis","randomized clinical trial","intravascular lithotripsy","baloon PCI","2025-12-18",{"date":393,"type":40},"2026-01-05",{"date":395,"type":40},"2025-10-22",{"date":397,"type":19},"2031-09",{"name":399,"class":47},"University Hospital, Clermont-Ferrand",{"id":401,"slug":402,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":408,"targetDuration":410,"studyType":59,"phases":4,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":48},"100610765","registry-of-coronary-disease-outcomes-revascularizing-with-drug-coated-balloons-100610765","NCT07231835","Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons","RECORD-DCB: Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons","RECORD-DCB","Inclusion Criteria:\n\n* Patients undergoing PCI with the Protégé paclitaxel-eluting DCB\n* Age ≥ 18 years\n* Presence of a de novo lesion or in-stent restenosis in a native coronary artery or a in a bypass graft and suitable for PCI\n* Reference vessel diameter between 2.0 - 4.5 mm\n* Patient suitable for dual antiplatelet therapy (DAPT)\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Allergy to paclitaxel",{"count":409,"type":19},3000,"5 Years","The primary aim of this registry is to systematically collect and analyze real-world data on all patients undergoing PCI with the Protégé paclitaxel-eluting DCB to evaluate procedural outcomes, long-term efficacy, and safety across various clinical indications. This registry aims to assess the clinical effectiveness of DCB therapy across diverse patient populations, including those with stable coronary artery disease (CAD) and acute coronary syndromes (ACS), as well as various lesion subsets, encompassing (but not limited to) in-stent restenosis (ISR), de novo coronary lesions, small vessel disease, bifurcation and calcified lesions, coronary bypass graft lesions, and patients at high risk of bleeding. Additionally, the study aims to identify predictors of success, complications, and optimal treatment strategies to further refine the use of DCBs.",[27,203,413,414,415,416],"Paclitaxel","CAD - Coronary Artery Disease","ACS (Acute Coronary Syndrome)","Stable Coronary Artery Disease (CAD), Myocardial Infarction","2025-11-14",{"date":419,"type":40},"2025-11-17",{"date":421,"type":40},"2025-11-11",{"date":423,"type":19},"2034-09-30",{"name":425,"class":47},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":20,"phases":435,"briefSummary":436,"conditions":437,"keywords":438,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":48},"100594876","phase-4-dual-antiplatelet-therapy-escalation-from-standard-dose-clopidogrel-to-low-dose-prasugrel-in-patients-with-high-bleeding-and-ischemic-risk-undergoing-pci-a-prospective-randomized-pharmacodynamic-study-tailor-bleed-2-100594876","NCT07025148","Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)","Switching From Clopidogrel to Low-dose Prasugrel in Patients at Dual-risk Following Percutaneous Coronary Intervention (TAILOR-BLEED-2)","Inclusion Criteria:\n\n* Patients with high bleeding risk (defined according to the ARC-HBR criteria) who have undergone PCI and are on maintenance treatment with DAPT, consisting of low-dose aspirin (81mg qd) with clopidogrel (75 mg qd) as part of standard of care for at least 30 days.\n* Age ≥18 years.\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* Prior cerebrovascular event.\n* PCI within 30 days.\n* Hemodynamic instability.\n* On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban) or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis).\n* Hypersensitivity to Aspirin, Clopidogrel, or Prasugrel.\n* Known hematologic malignancies or thrombocytopenia (platelet count \\\u003C80x106\u002FmL).\n* Known hemoglobinopathies or anemia (hemoglobin \\\u003C9 g\u002FdL)\n* Pregnant and breastfeeding women \\[women of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study\\].",{"count":434,"type":19},40,[174],"The primary aim of this study is to investigate the PD effects of switching from standard-dose clopidogrel dose to low-dose prasugrel versus continuing standard-dose clopidogrel in patients at dual-risk (HBR defined as the HBR-ARC criteria and HIR defined as ABCD-GENE score ≥10) following PCI. We hypothesize that in patients at dual-risk, switching from standard-dose clopidogrel to low-dose prasugrel will be superior to continuing standard-dose clopidogrel in terms of platelet reactivity.",[121,27],[304,439,333],"Dual antiplatelet therapy","2025-10-31",{"date":126,"type":40},{"date":443,"type":40},"2025-10-01",{"date":445,"type":19},"2027-11-01",{"name":447,"class":47},"University of Florida",{"id":449,"slug":450,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":11,"sex":15,"minAge":456,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":20,"phases":459,"briefSummary":461,"conditions":462,"keywords":465,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":48},"100605618","phase-3-safety-and-efficacy-of-very-short-dapt-in-older-patients-undergoing-pci-100605618","NCT07164859","Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI","Safety and Efficacy of Very Short Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy in Older Patients Undergoing Percutaneous Coronary Intervention (SOLOPCI)","SOLOPCI","Inclusion Criteria:\n\n* Patients ≥ 65 years\n* Successfully treated with percutaneous coronary intervention (PCI) with ≥ 1 drug-eluting stent (final TIMI 3 flow and visually estimated residual diameter stenosis \\\u003C30%) for acute coronary syndrome (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction and unstable angina) or chronic coronary syndrome (elective PCI). Inclusion is possible after the last PCI procedure in staged procedure.\n* Randomization must be performed before the discharge from the study site.\n* Written informed consent\n* Social security affiliated\n\nExclusion Criteria:\n\n* PCI without drug-eluting stent implantation or with a bioresorbable scaffold\n* Planned coronary artery bypass grafting or cardiac surgery\n* Any planned surgery within 12 months unless intended antiplatelet therapy could be maintained throughout the peri-surgical period\n* Index PCI for stent thrombosis or chronic total occlusion\n* Need for oral anticoagulation therapy\n* Known hypersensitivity or allergy to aspirin, clopidogrel, ticagrelor or prasugrel\n* Use of fibrinolytic therapy within 24 hours of PCI\n* Severe renal insufficiency (MDRD creatinine clearance \\\u003C 30 ml\u002Fmin\u002Fm2) and\u002For dialysis\n* Increased bleeding risk (prior hemorrhagic stroke; stroke \\\u003C 30 days; brain injury\\\u003C6 months; history of intracranial tumor or intracranial hemorrhage; internal bleeding\\\u003C6 weeks; active bleeding; anemia (hemoglobin ≤ 8 g\u002Fdl) or thrombocytopenia (platelets \\\u003C 100 000 G\u002FL); major surgery\\\u003C3 weeks)\n* increased thrombotic risk related to the patient (previous stent thrombosis, ≥ 2 previous myocardial infarction, symptomatic peripheral artery disease, chronic systemic inflammatory disease treated with corticoids or immunosuppressive drug) or the procedure (left main treated, ≥3 stents\u002Ftreated lesions, total length of stents\\>60mm, bifurcation lesion with stents in each branch, stenting of the last patent vessel)\n* Life expectancy less than 1 year\n* Participation in another interventional trial\n* Patients considered as vulnerable by the investigators because of medical, psychological or social conditions:\n\n  * Patients with known or discovered severe cognitive impairment\n  * Patients with treated or untreated severe psychological or psychiatric conditions\n  * Patients with uncorrected severe hearing or visual handicap\n  * Patients with addictive alcohol, drug or substance abuse\n  * Patients with protective measures (guardianship, tutorship, curatorship)\n  * Any other condition considered by the investigators as not warranting informed consent\n* patients with poor quality of the downstream territory with diffuse distal coronary disease\n* women of childbearing potential: non menopaused -with no menses for 12 months without an alternative medical cause- and not permanently sterilized -hysterectomy, bilateral salpingectomy or bilateral oophorectomy-","65 Years",{"count":458,"type":19},1700,[460],"PHASE3","The goal of this clinical trial is to learn if reducing the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (short treatment regimen, stopping aspirin at day 7) is as safe and efficient as the standard DAPT duration (standard treatment regimen) in elderly patients ≥ 65 years.\n\nThe main questions it aims to answer are:\n\nDoes the reduction of the duration of DAPT reduces rates of bleeding without increasing the risk of cardiovascular events? Researchers will compare a short treatment by DAPT (7 days, followed by single antiplatelet therapy) to a standard treatment duration by DAPT (3 to 12 months) after successful percutaneous coronary intervention with ≥ 1 drug-eluting stent.\n\nParticipants will:\n\n* Take aspirin for 7 days in one group or 3 to 12 months in another group\n* Be contacted by phone at 7 days, 14 days, 21 days, 30 days, 3 months, 6 months and 12 months after hospital discharge\n* Keep a diary of any bleeding or cardiovascular events occurring during the study period",[382,27,463,464],"Antiplatelet Therapy","Elderly (People Aged 65 or More)",[466,467,468],"antiplatelet therapy","percutaneous coronary intervention","elderly","2025-09-25",{"date":443,"type":40},{"date":472,"type":19},"2025-10",{"date":474,"type":19},"2029-10",{"name":476,"class":47},"Vincent ROULE",{"id":478,"slug":479,"hasResults":11,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":20,"phases":487,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":504,"locationsCount":48},"100604763","phase-4-efficacy-and-safety-of-shexiang-baoxin-pillmuskardia-in-the-treatment-of-acute-myocardial-infarction-100604763","NCT07153744","Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction","Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction: A Prospective, Multicenter, Pragmatic Randomized Controlled Real-World Study","MUST Ⅱ","Inclusion Criteria:\n\n* Aged 18 years or older, regardless of gender\n* In accordance with the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes , meeting the diagnostic criteria for acute myocardial infarction, including typical chest pain lasting for ≥20 minutes, electrocardiographic manifestations of ST-segment elevation (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), and serum high-sensitivity troponin (hs-cTn) levels exceeding the 99th percentile of the upper reference limit at least once with dynamic changes\n* Presenting for treatment within \\\u003C24 hours of symptom onset and scheduled to undergo PCI\n* The patient or their guardian has signed the informed consent form\n\nExclusion Criteria:\n\n* Having contraindications to PCI treatment\n* Being allergic to Shexiang Baoxin Pills, unable to tolerate them, or having other conditions that prevent completion of the trial drug administration\n* Being pregnant, planning to become pregnant, or breastfeeding women\n* Having participated in other clinical studies within 3 months\n* Being deemed unsuitable for inclusion in this study by the researcher",{"count":486,"type":19},9588,[174],"This study aims to evaluate the value of Shexiang Baoxin Pill (MUSKARDIA) in patients with acute myocardial infarction (AMI) through a prospective, multicenter, pragmatic randomized controlled real-world study. It seeks to validate its efficacy in reducing cardiovascular event risk during the peri-PCI period, as well as its effects on cardiac function, quality of life , and relevant biomarkers. Through this research, we expect to provide higher-quality evidence for the application of SBP in AMI patients undergoing PCI, thereby further optimizing comprehensive treatment strategies for AMI.",[490,27],"Acute Myocardial Infarction (AMI)",[295,492,67,493,494,495,496,497],"AMI","PCI","Shexiang Baoxin Pill","MUSKARDIA","Shexiang Baoxin Pill(MUSKARDIA)","SBP","2025-08-26",{"date":500,"type":40},"2025-09-04",{"date":502,"type":19},"2025-09-01",{"date":159,"type":19},{"name":505,"class":223},"Shanghai Hutchison Pharmaceuticals Limited",{"id":507,"slug":508,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":20,"phases":514,"briefSummary":515,"conditions":516,"keywords":520,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":534,"locationsCount":4},"100604931","the-effect-of-cardiac-rehabilitation-on-left-ventricular-remodeling-in-patients-undergoing-primary-percutaneous-coronary-intervention-for-acute-myocardial-infarction-100604931","NCT07155928","The Effect of Cardiac Rehabilitation on Left Ventricular Remodeling in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction","Inclusion Criteria:\n\n1. Underwent successful primary PCI within 24 hours of symptom onset.\n2. Hemodynamically stable and able to participate in rehabilitation.\n\nExclusion Criteria:\n\n1. Stage IV Heart failure, LVEF \\\u003C 30%\n2. Life-threatening arrhythmias\n3. Unstable Angina\n4. Severe Valvular Diseases\n5. Uncontrolled Hypertension\n6. CKD Stages IV and V\n7. Hypothyroidism\n8. Cardiomyopathy\n9. Inability to ambulate or consent",{"count":513,"type":19},100,[22],"Cardiac rehabilitation has proven to improve the functional capacity of patients who had acute myocardial infarction. However, its effect on Left ventricular remodeling following an MI event treated with Primary PCI is not yet fully understood. So, for this randomized controlled trial our objectives are as follows:\n\n* Primary: To assess the effect of a structured CR program on LV remodeling parameters (LVEF, LVESV, LVEDV, LVESD, LVEDD + SWMA) in STEMI patients treated with primary PCI.\n* Secondary: To evaluate changes in exercise capacity, heart rate recovery and clinical outcomes such as major adverse cardiovascular events and the effect of CR on the patients' Quality of Life.\n\nThese results will be compared to the same parameters in a control group that will not undergo cardiac rehabilitation to properly assess the effect of cardiac rehab.\n\nParticipants in the intervention group will be asked to undergo a supervised CR program based on published guidelines (FITT principle). The core will be a moderate-intensity aerobic exercise regimen (e.g. treadmill or cycle ergometer) 2-3 times per week for 12 weeks. Each session will last \\~20-60 minutes of exercise followed by cool-down, with intensity gradually increased to High intensity interval training (HIIT) in low-moderate risk individuals, as it has shown better improvement in cardiovascular health while being safe in MI patients. Resistance exercises (e.g. light weights or band exercises) will also be included twice weekly. Exercise dose (frequency, intensity, time) will be tracked. Physical therapists will supervise all sessions in an outpatient CR facility or affiliated gym. Patients' vitals and ECG will be monitored during initial sessions for safety.",[490,517,27,518,519],"PCI Patients","Primary Percutaneous Coronary Intervention","Left Ventricle Remodeling",[521,295,518,522,523,524,525,526,527,528,300,529],"Cardiac Rehabilitation","Left Ventricular Remodeling","Ejection fraction","End-systolic volume","End-systolic diameter","End-diastolic volume","End-diastolic diameter","Functional capacity","Resistance Training",{"date":500,"type":40},{"date":532,"type":19},"2025-11",{"date":254,"type":19},{"name":535,"class":47},"Assiut University",{"id":537,"slug":538,"hasResults":11,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":11,"sex":15,"minAge":544,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":20,"phases":547,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":559,"leadSponsor":561,"locationsCount":257},"100591843","medipixel-xa-assisted-pci-in-coronary-artery-disease-100591843","NCT06985693","Medipixel XA-Assisted PCI in Coronary Artery Disease","Medipixel XA-Assisted Percutaneous Coronary Intervention in Coronary Artery Disease: A Prospective Multicenter Study","MAP I","Inclusion Criteria:\n\n* Silent ischemia, stable or unstable angina, or myocardial infarction\n* De novo coronary lesion eligible for DES implantation\n* Lesions analyzable by MPXA\n\nExclusion Criteria:\n\n* Comorbidity with a life expectancy \\\u003C12 months\n* Intolerant of antithrombotic therapy\n* Significant anemia, thrombocytopenia, or leucopenia\n* History of major hemorrhage (intracranial, gastrointestinal, and so on)\n* Chronic total occlusion lesion\n* Left main lesion\n* Severe calcification needing rotational atherectomy\n* Lesions not analyzable by MPXA","19 Years",{"count":546,"type":19},830,[22],"This prospective, multicenter, single-arm, interventional study evaluates the effectiveness and safety of Medipixel XA-Assisted Percutaneous Coronary Intervention (MPXA-PCI) in patients with coronary artery disease (CAD). The study aims to assess procedural success rates and clinical outcomes associated with the novel MPXA-assisted PCI strategy in a real-world clinical setting.\n\nA total of 830 patients with de novo coronary lesions eligible for drug-eluting stent (DES) implantation will be enrolled. All participants will undergo MPXA-assisted lesion assessment to optimize balloon and stent selection. The primary outcome is target vessel failure (TVF) at 12 months, defined as a composite of cardiac death, target vessel-related myocardial infarction, and clinically driven target vessel revascularization. Secondary outcomes include procedural success, angiographic results, and periprocedural complications.\n\nThis study will provide evidence regarding the clinical applicability and safety of artificial intelligence-assisted quantitative coronary analysis (AI-QCA) technology for optimizing PCI procedures.",[27,121],[551,552,553,554],"Artificial Intelligence","Quantitative Coronary Analysis","Medipixel","MPXA","2025-05-15",{"date":557,"type":40},"2025-05-22",{"date":555,"type":40},{"date":560,"type":19},"2028-05",{"name":562,"class":47},"CHA University",{"id":564,"slug":565,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":318},"100587683","double-kissing-crush-vs-controlled-balloon-crush-techniques-for-complex-coronary-bfurcation-lesions-100587683","NCT06931574","Double Kissing-crush vs Controlled Balloon-crush Techniques For Complex Coronary Bfurcation Lesions","Comparison of Cardiovascular Outcomes of Double Kissing-crush vs Controlled Balloon-crush Techniques For Complex Coronary Bifurcation Lesions","Inclusion Criteria:\n\n* Aged \\>18\n* PCI with either DK-crush or Controlled balloon-crush\n* Complex coronary bifurcation lesion (Medina 0.1.1, Medina 1.1.1)\n\nExclusion Criteria:\n\n* Non-complex bifurcation anatomy\n* Bail-out 2-stent (reverse modified mini-crush)\n* ST-elevation myocardial infarction\n* Cardiogenic shock status\n* In-stent restenosis\n* A previous of coronary artery bypass grafting\n* Implantation of bare-metal stent\n* End-stage hepatic or renal disease\n* \\\u003C1-year life expectancy",{"count":267,"type":19},"The Crush technique for coronary bifurcation lesions has evolved significantly since its introduction to the literature by Colombo et al. in 2003, with several iterations, including double kissing balloon inflation. The main disadvantage of the historical Crush technique is the low success rate of the final kissing balloon inflation. An improvement came with the introduction of double kissing crush stenting aiming for the shorter protrusion and kissing balloon dilation performed before and after main branch stent implantation. The double kissing crush provides a significant reduction in major adverse cardiovascular events compared to Provisional stenting, Crush, and Culotte techniques. Recently, a novel modified mini-crush technique (controlled balloon-crush) has been introduced to the literature and is one of the most up-to-date crush techniques. The main advantage of this technique over the contemporary mini-crush technique is that the side branch can be easily rewired, and the 1:1 size non-compliant balloon can easily pass through the crushed stent structure in the ostial part of the side branch. The basic rationale of this is that the crushing of the side branch stent is done in a more controlled manner (by slowly deflation of the side branch stent balloon), and this causes less disruption of the stent cells. To date, no data compares the mid-term outcomes of double kissing crush and controlled balloon-crush stenting techniques in patients with complex coronary bifurcation lesions. Hence, this study aimed to determine the clinical results of double kissing crush and controlled balloon-crush techniques under mid-term follow-up.",[121,27,573],"Bifurcation Coronary Disease","2025-04-15",{"date":576,"type":40},"2025-04-17",{"date":578,"type":40},"2025-04-01",{"date":580,"type":19},"2026-12-30",{"name":582,"class":162},"Istanbul Mehmet Akif Ersoy Educational and Training Hospital",{"id":584,"slug":585,"hasResults":11,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":20,"phases":593,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":108},"100569276","comparison-of-an-ultra-low-strut-thickness-everolimus-eluting-biodegradable-polymer-stent-versus-durable-polymer-everolimus-eluting-stents-in-patients-treated-with-percutaneous-coronary-intervention-100569276","NCT06692140","Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention","Randomized Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention in an All Comer Population (The SORT OUT XII Trial)","SORT OUT XII","Inclusion Criteria:\n\n* All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Not able to consent to study participating (eg. intubated patients)\n* Unstable circuit or in cardiogenic shock and therefore not able to understand the information and purpose of the study\n* Do not speak Danish\n* Already included in the SORT OUT XII study\n* Life expectancy \\\u003C1 year\n* Allergic to study related treatment",{"count":592,"type":19},3150,[22],"The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention",[596,91,27],"Ischemia, Myocardial",[332,598],"outcome","2024-12-04",{"date":601,"type":40},"2024-12-09",{"date":603,"type":40},"2024-11-16",{"date":605,"type":19},"2032-07-01",{"name":607,"class":47},"Odense University Hospital",{"id":609,"slug":610,"hasResults":11,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":616,"targetDuration":4,"studyType":20,"phases":618,"briefSummary":619,"conditions":620,"keywords":623,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":48},"100565941","efficacy-and-safety-of-shortening-dual-antiplatelet-therapy-duration-with-ivus-guidance-in-pci-patients-100565941","NCT06648720","Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients","Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients: a Multicenter, Randomized Controlled Trial","SHORTDAPT","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).\n* Patients with the following clinical indications for PCI:\n\n  * Unstable Angina: Prolonged chest pain at rest, new-onset angina within the past 2 months, or increasing frequency\u002Fseverity of angina attacks.\n  * Acute Myocardial Infarction (MI): With or without ST-elevation.\n  * Chronic Coronary Syndrome: Requiring coronary revascularization.\n* Patients who agree to participate and provide informed consent.\n\nExclusion Criteria:\n\n* Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.\n* Neurological Complications: Stroke or any permanent neurological deficits within the last 3 months.\n* Coronary Artery Bypass Graft Surgery: History of CABG surgery.\n* Planned Surgery: Patients who have surgeries planned within the next 12 months.\n* Severe Chronic Kidney Disease: Patients with an estimated glomerular filtration rate (eGFR) of less than 20 ml\u002Fmin\u002F1.73 m² or patients on dialysis.\n* Chronic Anticoagulation Therapy: Patients requiring chronic oral anticoagulation (e.g., warfarin, DOACs) beyond DAPT.\n* Thrombocytopenia: Platelet count less than 100,000\u002Fmm³.\n* Contraindications to Antiplatelet Therapy: Allergy or intolerance to aspirin or P2Y12 inhibitors.\n* Liver Disease: Patients with cirrhosis or significant liver dysfunction.\n* Limited Life Expectancy: Patients with a life expectancy of less than 12 months due to other non-cardiac conditions.\n* Other Medical Conditions: Any condition that might interfere with adherence to the study protocol or follow-up schedule.",{"count":617,"type":19},3566,[22],"This study is designed to assess the efficacy and safety of de-escalating dual antiplatelet therapy (DAPT) at 1 month compared to the standard 12 months of therapy in patients undergoing percutaneous coronary intervention (PCI) guided by intravascular ultrasound (IVUS). The main outcomes measured will include major adverse cardiovascular and cerebrovascular events (NACCE), bleeding events, and target vessel failure (TVF). The goal is to evaluate whether a shorter duration of DAPT is non-inferior to the standard 12-month regimen in preventing ischemic events while reducing the incidence of bleeding.",[121,27,621,622],"Intravascular Ultrasound","Dual Antiplatelet Therapy",[624,625,626,121],"Shortening DAPT duration","Intravascular Ultrasound (IVUS)","Percutaenous Coronary Intervention (PCI)","2024-10-16",{"date":629,"type":40},"2024-10-18",{"date":631,"type":19},"2025-03-01",{"date":633,"type":19},"2029-03-01",{"name":635,"class":47},"University Medical Center Ho Chi Minh City (UMC)"]